COMPANY

Rational Vaccines Inc.

Profile checked Oct 10, 2026

Keywords: Genital Herpes herpes simplex

Funding and NIH signals

NIH award NIH awarded $999K (SBIR Phase II 5R44AI170133-03, continuation, notice May 13, 2026). NIH RePORTER 5R44AI170133-03 (May 13, 2026)
Evidence (1 event)
- May 13, 2026 · NIH RePORTER 5R44AI170133-03
  Organization: RATIONAL VACCINES, INC.; City/State: WOBURN, MA; Project number: 5R44AI170133-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 999160; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

May 13, 2026 Grant Government grant — SBIR: $999,160 (annual award, as published), announced May 13, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jan 24, 2025 Grant Government grant — SBIR: $986,717 (annual award, as published), announced Jan 24, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 3, 2022 Trial start —: A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease source ↗

Last 2 years.

May 13, 2026 Government grant — SBIR: $999,160 (annual award, as published), announced May 13, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jan 24, 2025 Government grant — SBIR: $986,717 (annual award, as published), announced Jan 24, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05500053	A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease	Not listed	Completed	Aug 3, 2022	Dec 31, 2022 (actual)

Annual award amounts. Total $849K.

Aug 3, 2023 NIH award 1R44AI170133-01A1 FY2023: $288,088 awarded for that fiscal year; activity R44 (SBIR); PI GERSHBURG, EDWARD; recipient as written: RATIONAL VACCINES, INC., WOBURN, MA. Preclinical Evaluation of a Novel Immun source ↗
Jul 28, 2023 NIH award 1R43AI176913-01 FY2023: $291,480 awarded for that fiscal year; activity R43 (SBIR); PI GERSHBURG, EDWARD; recipient as written: RATIONAL VACCINES, INC., WOBURN, MA. Development of a Highly Specific and Sens source ↗
Aug 31, 2022 NIH award 1R43AI165060-01A1 FY2022: $269,616 awarded for that fiscal year; activity R43 (SBIR); PI GERSHBURG, EDWARD; recipient as written: RATIONAL VACCINES, INC., WOBURN, MA. A novel prophylactic and therapeutic va source ↗